⭐️Ustekinumab+MTX vs. UST+PBO in PsA? ➡️Additional MTX has no positive impact on UST efficacy for arthritis, enthesitis, dactylitis, skin, QoL, & function. *️⃣Thus, no evident to add or maintain ongoing MTX when starting UST Late-Breaking Poster#12. #ACR21 @RheumNow #ACRBest https://t.co/k96PPUtwct

Retrospective cohort study FORWARD databank : ⭐️ 🔼opioid use was associated with higher HAQ-DI and BASDAI scores among patients with PsA or AS Annualized avg opioid use and costs 🔼with 🔼HAQ-DI and BASDAI scores for patients in both cohorts Abst#1117 #ACRBest @RheumNow https://t.co/KB9QUITbAe

*️⃣Abst#1800 observed that a changing pattern of purine, lipid, & amino acid metabolites occurred during transition from PsO to PsA. *️⃣Compared to pts w/ Pso that didn't progress to PsA, those that progressed had elevated levels of guanine! Potential biomarkers? #ACR21 @RheumNow https://t.co/iQh1ZapDMB

⭐️Immune phenotyping of 45 patients with Pso and 41 PsA pts showed a number of cell subsets significantly different in Pso vs PsA ⭐️Future possibility of using a combination of selected immune cell subsets as a method for detecting PsA in Pso pts Abst#1774 #ACR21 @Rheumnow https://t.co/ER1MPOvMa6

Abst#1774 identified a blood-based immune profile with a machine-learning approach that discriminates PsA from Pso. ➡️↑ proportions of differentiated CD4+CD196+CD183–CD194+ and CD4+CD196–CD183–CD194+ T-cells in PsA #ACR21 @RheumNow https://t.co/64uhJCd2qo

#Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #ustekinumab loses throne in #psoriasis and #psoriatic arthritis except maybe if concomitant inflammatory bowel disease post TNFi? Rapidly evolving PsA Rx. Abst#1773 #ACR21 @RheumNow https://t.co/Dkf2DFFsSK

• Olga Petryna on Twitter: "Abst1773 #ACR21 @rheumnow guselkumab outperforms…